Drug news: Sorilux and Duobrii (US only), gels
Good news, everyone. There are new, promising-looking medications on the market.
Duobrii was just FDA-approved in June:
DUOBRII Lotion combines two well-known ingredients into a single, first-of-its-kind topical treatment. The strong antiinflammatory agent (halobetasol propionate) works to clear plaques, while the vitamin A derivative (tazarotene) helps extend the clearing process.
This product comes out of studies such as this one that shows that tazarotene, a retinoid, counteracts the adverse effects of topical steroids. In this case, the medication uses halobetasol, a potent steroid. It only comes as a lotion.
Sorilux is not a new drug, but it’s a new formulation. It’s a spray foam version of calciptoriene (aka calcipotriol), a synthetic form of vitamin D3. Unlike steroids, calcipotriene can be used indefinitely with no adverse effects.
The foam makes it easy to apply to large areas, and it dries completely within a minute or two. It’s not greasy and doesn’t leave much residue.
The web site has a $0 co-pay card you can print out to reduce your medical expenses.
For those with skin psorasis who don’t like greasy ointments, I’d also like to remind everyone that an increasing selection of gels are becoming available:
- Lidex Gel (fluocionide 0.05%) is available in the US, both as a brand product and as a generic.
- Zatamil (mometasone) is available in Australia.
- Dovobet Gel (betamethasone + calcipotriene) is available in the UK.
Gels are polymer-based and don’t contain any greasy petroleum products; they dry within minutes. Studies have found gels to be on par with ointments in terms of skin absorption, and better than creams and lotions.